Prevention of Recurrence in Depression with Drugs and CT

通过药物和 CT 预防抑郁症复发

基本信息

  • 批准号:
    6327011
  • 负责人:
  • 金额:
    $ 60.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-16 至 2007-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): It is commonly believed that the combination of antidepressant medications (ADM) and psychotherapy is more effective in the treatment of depression than is either treatment alone. There is evidence that adding cognitive therapy (CT) enhances the initial effects of ADM, but most of the relevant studies have suffered from low power. Moreover, findings from numerous studies suggest that CT has an enduring effect, but most of the evidence has been relevant to the prevention of relapse - the return of symptoms associated with the treated episode. There is little evidence on what is arguably the more critical prevention question: whether prior exposure to CT prevents recurrence - the onset of new episodes. What is needed is a study that is sensitive enough to detect the benefits that might accompany the addition of CT to ADM, and that can begin to address the attendant cost-effectiveness questions. The proposed design combines the goals and methods of efficacy and effectiveness research to these ends. We plan to randomly assign 450 depressed outpatients (150 at each of three sites) to ADM alone or to ADM plus CT. All patients will be treated to remission with a clinically representative ADM regimen, and half will, in addition, receive CT. Remitted patients will then be continued on medications for up to 12 months until they meet criteria for recovery, during which time CT will be continued as clinically indicated for patients in combined treatment. Once recovered, patients will be randomly assigned to either maintenance medications or medication withdrawal. Shortly thereafter, patients who have been receiving CT will be withdrawn from it as well. Patients will then be followed for a three-year period for the purpose of detecting recurrences. The main hypotheses are: (1) initial response will be better in ADM plus CT, relative to ADM alone; and (2) prior exposure to CT will protect against subsequent recurrence following medication withdrawal, to the same extent as maintenance ADM. Analyses will be employed to estimate the relative cost-effectiveness of adding CT to ADM for acute response and recurrence prevention.
描述(由申请人提供):通常认为, 抗抑郁药物(ADM)和心理治疗的组合更多 治疗抑郁症的效果比单独使用任何一种都好。那里 有证据表明,增加认知疗法(CT)可以增强 ADM,但大多数相关的研究都遭受了低功率。此外,委员会认为, 许多研究的结果表明,CT具有持久的效果,但大多数 的证据一直与预防复发-返回的 与治疗事件相关的症状。几乎没有证据表明 可以说是更关键的预防问题: 防止复发-新的发作的开始。我们需要的是一项研究, 足够敏感,可以检测到添加 CT到ADM,这可以开始解决随之而来的成本效益问题 问题.所提出的设计结合了有效性的目标和方法, 为达到这一目的而进行的有效研究。我们计划随机分配450名抑郁症患者 门诊患者(三个站点各150例)单独ADM或ADM加CT。所有 患者将接受临床代表性ADM治疗至缓解 方案,一半将另外接受CT。康复患者将在 持续用药长达12个月,直到符合以下标准 恢复期间,将根据临床指征继续进行CT检查, 患者进行综合治疗。一旦康复,患者将被随机 分配给维持药物或停药。不久 此后,已接受CT的患者将退出CT, 好.然后将对患者进行为期三年的随访,目的是 检测复发。主要假设是:(1)初始反应将是 ADM + CT组优于ADM组;(2)CT暴露后, 预防停药后的复发, 与维护ADM相同的程度。将采用分析来估计 在ADM中添加CT治疗急性反应的相对成本效益, 预防复发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN DENNIS HOLLON其他文献

STEVEN DENNIS HOLLON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN DENNIS HOLLON', 18)}}的其他基金

Improving Outcomes in Depression in Primary Care in a Low Resource Setting
改善资源匮乏的初级保健中抑郁症的治疗效果
  • 批准号:
    10624403
  • 财政年份:
    2022
  • 资助金额:
    $ 60.62万
  • 项目类别:
An Immersive Virtual Reality Peer Support Application for Individuals with Opioid Use Disorder: Development and Initial Evaluation
针对阿片类药物使用障碍患者的沉浸式虚拟现实同伴支持应用程序:开发和初步评估
  • 批准号:
    10011746
  • 财政年份:
    2020
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    6987047
  • 财政年份:
    2005
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    7656826
  • 财政年份:
    2005
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    7256914
  • 财政年份:
    2005
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    7459104
  • 财政年份:
    2005
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    7126095
  • 财政年份:
    2005
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and CT
通过药物和 CT 预防抑郁症复发
  • 批准号:
    6869612
  • 财政年份:
    2002
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and Cognitive Therapy
通过药物和认知疗法预防抑郁症复发
  • 批准号:
    7392335
  • 财政年份:
    2002
  • 资助金额:
    $ 60.62万
  • 项目类别:
Prevention of Recurrence in Depression with Drugs and Cognitive Therapy
通过药物和认知疗法预防抑郁症复发
  • 批准号:
    7777247
  • 财政年份:
    2002
  • 资助金额:
    $ 60.62万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了